Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,39 +0,30%
EUR/USD 1,0884 +0,61%
FTSE 100 8.445,80 +0,21%
Germany40^ 18.875,90 +0,85%
Gold spot 2.387,47 +1,25%
NY-Nasdaq Composite 16.511,18 +0,75%

Stijgers

INPOST
+6,22%
NX FIL...
+6,15%
JDE PE...
+4,86%
WDP
+4,26%
ASMI
+2,87%

Dalers

ABN AM...
-6,11%
AMG Cr...
-3,25%
Air Fr...
-3,06%
Fugro
-2,30%
Pharming
-2,07%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links